Tiostar

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tiostar

Property Description
Active ingredient Famotidine
Form Tablet, Oral Suspension, IV Solution
Pharmacological class Histamine H₂-Receptor Antagonist
General purpose Reduction of gastric acid production
Origin Synthetic

Tiostar: Defining the Antisecretory Agent

Tiostar is a synthetic pharmaceutical preparation containing the single active substance, Famotidine. This medicine is precisely classified within the high-level pharmacological class of Histamine H₂-Receptor Antagonists, often referred to as H₂-blockers, and its fundamental role is that of an antisecretory agent. Famotidine's identity is chemically defined by the formula C8H15N7O2S3, confirming its definitive structure as a synthetic compound. This classification establishes its essential function as an agent that modifies the processes of gastric acid production.

The Physical Forms and Administration Modality

Tiostar is manufactured in multiple drug forms to accommodate various patient needs and therapeutic requirements. The available forms include the standard Oral Tablet, a readily available Chewable Tablet, and the liquid Oral Suspension suitable for the general oral route of administration. Furthermore, the medication is prepared as a sterile Intravenous Solution for IV administration when rapid systemic delivery is clinically indicated. The drug is consistently provided as a preparation containing a single active ingredient.

General Purpose: Targeting Gastric Acid Production

The general purpose of Tiostar is to achieve a controlled decrease in gastric acid production, thereby mitigating the physical discomfort associated with hyperacidity. The Histamine H₂-Receptor Antagonist works through a mechanism of competitive inhibition, preventing the natural chemical histamine from binding to receptors on the acid-secreting cells. This basic physiological action is used to maintain a less acidic environment, providing relief from discomfort related to acid-related gastrointestinal conditions and supporting heartburn prevention.

Regulatory References

  1. Famotidine: MedlinePlus Drug Information
  2. Histamine Type-2 Receptor Antagonists (H2 Blockers) - LiverTox - NCBI Bookshelf - NIH

What side effects are possible with Tiostar?

Possible Side Effects and Safety Information for Tiostar

Tiostar has an officially documented safety profile based on regulatory findings, with specific attention to certain serious adverse reactions and required monitoring procedures.

Key Safety Considerations

The most serious and clinically significant safety risk documented for Tiostar is Ocular Toxicity. This may manifest as changes in vision, including severe vision loss, and corneal ulceration. Due to this risk, the drug requires mandatory ophthalmological monitoring.

Category Documented Adverse Reactions (Examples)
Organ System Ocular Toxicity, including severe vision loss and corneal ulceration
Hepatobiliary Alanine aminotransferase increased
Dermatologic Alopecia (hair loss)
Vascular Epistaxis (nosebleed)

Safety Restrictions and Monitoring

Mandatory safety restrictions are an integrated part of the treatment protocol. A comprehensive ophthalmic examination is required prior to starting therapy and before every treatment cycle for the first nine cycles. Additionally, patients are required to use specific preventative measures, including mandatory premedication and topical eye care (such as cold packs, corticosteroid drops, and lubricating drops), to help reduce the risk of ocular adverse events.

Dosage modifications, including holding the dose, reducing the dose, or permanently discontinuing the drug, are explicitly required based on the severity and tolerability of any adverse reactions experienced by the patient. The official regulatory documents provide clear guidelines for these dose-modification protocols.

Overdose and Emergency Response

Overdose and when to seek help

Overdose Scope

Property Description
Documented Overdose Presentations Symptoms may include headache, dizziness, nausea, vomiting, and drowsiness. Severe manifestations reported in regulatory documents involve Central Nervous System (CNS) adverse reactions (e.g., hallucinations, seizures, agitation), abnormal heartbeat, and low blood pressure.
Physiological Systems Affected Overdose toxicity primarily affects the Central Nervous System and the Cardiovascular system. Potential Systemic/Hepatic effects have been noted.
Population-Specific Overdose Notes There is an increased risk of severe CNS adverse reactions in elderly patients and individuals with moderate to severe renal impairment due to higher systemic exposure.
When Immediate Medical Help Is Required Immediate medical attention is required in all cases of suspected overdose. This includes contacting a Poison Control Center or calling emergency services immediately.

Overdose Classifications

Classification Description
Severity Classification The documented outcomes range from non-specific adverse reactions to severe or life-threatening systemic outcomes that require immediate supportive intervention.
Management Constraints Regulatory documents confirm no specific antidote is known. Treatment is constrained to established symptomatic and supportive therapy, which includes monitoring of vital signs and ECG.

Connection to the overall overdose profile The regulatory profile for Famotidine overdose defines a spectrum of manifestations that can escalate to severe CNS and cardiovascular events. This risk assessment mandates that official guidance uniformly requires individuals to seek immediate medical help to ensure necessary symptomatic and supportive treatment and continuous hospital monitoring are initiated.

Therapeutic Uses of Tiostar

What Tiostar treats: main uses and benefits

Tiostar is a medication primarily used for the long-term management of chronic respiratory conditions. It belongs to a class of drugs known as long-acting muscarinic antagonists (LAMAs), which are designed to help keep the airways open over an extended period.

Main Uses

The medication is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD). This includes several progressive lung conditions that cause breathing difficulties, such as:

  • Chronic Bronchitis: A condition characterized by a long-term cough and mucus production due to inflammation of the bronchial tubes.
  • Emphysema: A condition involving damage to the air sacs (alveoli) in the lungs, which reduces the surface area available for oxygen exchange.

Tiostar is intended for regular, daily use to manage persistent symptoms rather than for the immediate relief of sudden breathing distress.

How It Works

The active ingredient in Tiostar works by blocking muscarinic receptors located on the smooth muscle cells of the airways. Under normal circumstances, certain natural chemicals in the body can cause these muscles to tighten. By inhibiting this action, the medication helps the muscles stay relaxed, a process known as bronchodilation. This helps to:

  • Increase the diameter of the airways.
  • Reduce airflow limitation.
  • Make it easier for air to move in and out of the lungs.

Benefits of Treatment

When used consistently as part of a long-term management plan, Tiostar provides several clinical benefits for individuals with chronic airflow obstruction:

  • Symptom Reduction: Regular use can lead to a decrease in daily shortness of breath and chronic coughing.
  • Improved Lung Function: Maintenance therapy helps stabilize breathing capacity throughout the day and night.
  • Exacerbation Management: Treatment may help reduce the frequency and severity of flare-ups, which are periods where respiratory symptoms suddenly worsen.
  • Enhanced Exercise Tolerance: By making breathing more efficient, the medication can support a patient's ability to engage in daily physical activities and improve overall functional capacity.

Regulatory References

  1. DailyMed NIH Label for Famotidine

Eligibility and Restrictions for Use

Eligibility Scope

The use of Tiostar (Famotidine) is defined by official regulatory documents, outlining populations permitted to use the medicine, as well as those who require caution or are strictly prohibited.

Eligibility Status Applicable Population/Condition
Contraindicated Patients with a history of serious hypersensitivity reactions to Famotidine or to other Histamine H2-receptor antagonists.
Established Use Adults and older adults for all approved conditions, and pediatric patients (including infants) for specific, age-appropriate indications.
Restricted Use Individuals with impaired renal function (Creatinine Clearance < 60 mL/min) are in a restricted-use category, often requiring a lower dose due to the potential for drug accumulation and Central Nervous System (CNS) adverse reactions. The geriatric population also requires monitoring for CNS adverse reactions.
Not Recommended Use during pregnancy is generally not recommended unless the potential benefits clearly justify the risks. Breastfeeding mothers should either discontinue the drug or cease nursing due to excretion in breast milk.
Caution Required Patients with a gastric ulcer must be evaluated to exclude the presence of gastric malignancy before starting treatment.

Regulatory Summary

Official labeling classifies non-eligibility into absolute contraindications (allergy) and conditional restrictions (renal function, pregnancy). Use is established in adults and in certain pediatric groups (some formulations are approved for use from birth), but tablets are generally not recommended for children weighing less than 40 kg.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Tiostar, containing Famotidine, has officially documented interaction patterns primarily related to its effect on gastric pH and its involvement in drug metabolism and clearance.


Pharmacokinetic Interaction Patterns

Famotidine's ability to reduce stomach acid can significantly reduce the systemic exposure of co-administered medicines that require an acidic environment for absorption, potentially leading to a loss of efficacy. This effect is documented for antifungals such as Ketoconazole and certain antiviral agents like Atazanavir, as well as Tyrosine Kinase Inhibitors.

Tiostar's administration requires separation from certain substances due to absorption interference or clearance inhibition:

  • Sucralfate and Antacids may interfere with Famotidine absorption, requiring administration to be separated by one to two hours or more.
  • Co-administration with Probenecid is advised to be avoided, as it inhibits Famotidine’s renal tubular secretion, causing a substantial increase in Famotidine plasma concentrations.
  • Co-administration with Tizanidine is also advised to be avoided, if possible, due to Famotidine’s effect on the CYP1A2 enzyme, which results in a substantial increase in Tizanidine blood levels.

Other Interaction Considerations

Famotidine has no documented augmentation of blood alcohol levels. The medication may be taken with or without food.

For patients with renal impairment, slower elimination leads to higher Famotidine systemic exposure, which increases the documented risk of specific CNS adverse reactions.

Mechanism of Action

Modulating Cellular Energy Pathways

Tiostar's active component engages mechanisms that enhance the compensatory activation of anaerobic glycolysis while concurrently supporting the activation of oxidative processes in the Krebs cycle. This dual action modulates energy substrate utilization within the cell, contributing to sustained ATP generation under conditions of reduced oxygen availability. This process leads to the maintenance of intracellular ATP concentrations, supporting essential cellular processes.


Antioxidant and Membrane Stabilization

The compound acts within the domain of cellular protection by exhibiting antioxidant and membranostabilizing activity. It directly activates the antioxidant system within tissues and inhibits lipid oxidation processes that typically lead to cellular damage. This engagement with free radical scavenging pathways influences the cellular redox state and inhibiting reactive oxygen species generation, which affects membrane fluidity and structural parameters.


Regulating Tissue Metabolism

Tiostar is relevant in systems that require targeted pathway adjustment for cellular turnover and metabolic function. The compound regulates cellular proliferation and differentiation pathways in hepatic tissue, influencing the rates of protein, carbohydrate, lipid, and pigment metabolism. This mechanism influences feedback regulation within metabolic pathways, which contributes to the modulation of pathway activity within specific tissues.

Dosage and Administration Information

How to Use Tiostar: Official Administration Guidelines

This section details the usage instructions for Tiostar (Famotidine). These guidelines define the routes of administration, dose ranges, and schedules used to ensure consistent application in clinical practice.


Administration Scope

Parameter Instruction
Route of administration Tiostar is approved for Oral administration (Tablet, Oral Suspension) and Intravenous (IV) injection.
Dosing schedule Regimens range from a low of 20 mg once daily (for maintenance or mild conditions) up to 40 mg twice daily (for conditions like erosive esophagitis). Dosing for pathological hypersecretory conditions may begin at 20 mg every 6 hours.
Timing in relation to meals The medication may be taken with or without food. Once-daily doses are frequently timed for administration before bedtime.
Preparation requirements The oral suspension form requires reconstitution by adding a specified volume of water prior to initial dispensing and use.
Population adjustments A dose reduction is required for patients with moderate to severe renal impairment (creatinine clearance below 60 mL/minute). In pediatric patients weighing less than 40 kg, non-tablet formulations are necessary to adhere to weight-based dosing.

Procedural Structure and Constraints

Official administration protocols define clear steps for usage. For oral administration, the dose is taken irrespective of food intake, and the twice-daily schedule is commonly set for morning and bedtime. The selection of a specific formulation, such as the oral suspension, is determined by the need for exact weight-based dosing in pediatric patients or for patients requiring an alternate dose not achievable with standard tablet strengths. These procedural rules standardize the administration pattern across various patient scenarios.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Tiostar

This overview summarizes the available research concerning Tiostar (famotidine), focusing on the types of studies conducted, the outcomes they measured, and what remains unclear in the research landscape. This summary is intended to provide factual context about the evidence and is not a substitute for medical advice or clinical interpretation.

Evidence for Ulcer Healing and GERD Symptoms

Research for active duodenal and benign gastric ulcers relies on short-term Randomized Controlled Trials (RCTs). These studies evaluated the ulcer healing rate via endoscopy and monitored patient-reported discomfort intensity. Findings describe patterns where healing rates were reported in higher proportions in one study group compared to placebo. Follow-up durations were limited (typically 4–8 weeks) for the acute phase, and comparative evidence against many current treatments is lacking.

For Gastroesophageal Reflux Disease (GERD), RCTs explored symptom resolution and change in symptom intensity in conditions characterized by fluctuating symptoms. Studies focusing on erosive esophagitis (EE) also examined endoscopic healing. Results were associated with higher proportions of patients reporting symptom change compared to placebo. Scientific reviews note evidence suggesting the acid-reducing effect may lessen over time, and long-term effects are not fully established.

Evidence in Special Populations and Research Gaps

Evidence for rare, high-acid-producing conditions is based on small-scale observational studies and case series, meaning sample sizes were modest. Research in pediatric populations also featured smaller samples, and studies in older adults indicate that drug processing can vary. Data for certain groups remain insufficient for broad conclusions.

Scientific reviews note that the evidence quality varies across studies due to older comparison arms, and limited information for long-term outcomes exists regarding continuous use for periods exceeding 12 months.

Key Studies & References

  1. Famotidine Oral/Intravenous: Official Drug Label and Prescribing Information Summary

Frequently Asked Questions (FAQ)

Common questions about Tiostar (FAQ)


Q: What kind of condition is Tiostar used for?

Official documents state that Tiostar, which contains Famotidine, is indicated for several acid-related conditions. This includes the treatment of active duodenal and gastric ulcers, symptomatic nonerosive gastroesophageal reflux disease (GERD), and certain pathological conditions that cause excessive acid secretion.


Q: Are there any known common side effects of Tiostar?

According to data from clinical trials, the most commonly reported adverse reactions are generally mild. These documented reactions include headache, dizziness, constipation, and diarrhea.


Q: Is a headache a common side effect described for Tiostar?

Yes, official prescribing information lists headache as one of the most common adverse reactions reported in studies.


Q: Does Tiostar interact with common over-the-counter pain relievers?

Tiostar's active ingredient, Famotidine, is sometimes available in a fixed-dose combination with ibuprofen, a type of NSAID pain reliever. Regulatory documents note a warning about the increased risk of gastrointestinal bleeding or ulcers when this combination is used.


Q: How long is Tiostar typically prescribed for?

The standard duration of use varies based on the condition being treated, but it is typically prescribed for short courses. For active ulcers, the course may be up to 8 weeks, while long-term use, such as up to one year, is sometimes prescribed to reduce the risk of ulcer recurrence.


Q: What is the risk of an allergic reaction to Tiostar?

The official product information specifies that Tiostar is contraindicated if an individual has a known history of serious hypersensitivity reactions to Famotidine or to other H₂-receptor antagonists. Serious allergic reactions may include symptoms such as hives, swelling, or difficulty breathing.


Q: Why does the official document mention a specific warning about a certain population?

Regulatory documents highlight a specific warning regarding Central Nervous System (CNS) adverse reactions, such as confusion or delirium. This warning is primarily directed toward elderly patients and those with moderate to severe renal (kidney) impairment.


Q: Does Tiostar affect mood or concentration?

Studies indicate that CNS adverse reactions, which can affect mood and concentration, have been reported. These effects, such as confusion, disorientation, anxiety, and changes in mood, are more commonly observed in elderly patients or those with pre-existing kidney problems.


Q: Is Tiostar a new kind of medication?

Tiostar contains the active ingredient Famotidine, which belongs to the class of H₂-receptor antagonists. The original approval for this active ingredient in the United States dates back to 1986.


Q: How quickly can one generally expect Tiostar to start working?

Official pharmacokinetic studies indicate that following oral administration, the onset of action, or the start of acid suppression, generally occurs within one hour. The peak effect is typically reached within 1 to 3 hours after the dose is taken.


Q: Is there a generic version of Tiostar available?

Yes, the active ingredient, Famotidine, is the generic drug and is widely available from multiple manufacturers as a generic option.


Q: What if I forget to take a dose of Tiostar?

Official patient information outlines a procedure where a missed dose may be taken when remembered. However, if it is almost time for the next dose, the procedure indicates the missed dose should be skipped to maintain the regular schedule.


Q: Is Tiostar safe for people with liver problems?

Official product characteristics describe a warning that monitoring of liver function may be required for patients receiving long-term treatment or high doses of Tiostar.


Q: Does Tiostar affect fertility?

Studies conducted in animals, as described in nonclinical toxicology reports, did not show any evidence that the drug affects fertility or reproductive performance.


Q: What happens if I stop taking Tiostar suddenly?

The official Summary of Product Characteristics contains a statement that abrupt withdrawal of the medication is advised against for patients who have long-standing ulcer disease after symptoms have been relieved.


Q: What are the non-medicinal ingredients in Tiostar?

The non-medicinal, or inactive, ingredients differ depending on the specific formulation (e.g., tablet vs. injection). For instance, some tablets contain lactose, while the sterile injectable solution includes L-aspartic acid, mannitol, and Water for Injection.


Q: Are there any restrictions on driving or operating machinery while using Tiostar?

Official regulatory documents indicate that due to the possibility of dizziness and somnolence (sleepiness), caution may be warranted regarding activities like driving or operating heavy machinery.


Q: What is the half-life of Tiostar?

Pharmacokinetic data indicates that the half-life, or the time it takes for half of the drug to be eliminated from the body, is typically between 2.5 and 3.5 hours. This half-life can become significantly longer in individuals with severe kidney impairment.


Q: Is Tiostar used in combination with other treatments?

Tiostar's active ingredient, Famotidine, is sometimes prepared as a fixed-dose combination product with other medicines, such as the NSAID ibuprofen. There is an explicit warning against using it with other acid-reducing agents.


Q: Does Tiostar change the results of any laboratory tests?

An adverse reaction reported in clinical trials is an increase in liver enzymes, such as Alanine Aminotransferase (ALT). This change in liver enzyme levels would affect the measurement of that specific laboratory blood test.


Q: What should I do if I suspect an interaction?

Regulatory patient information describes a general principle that for serious or unexpected symptoms, immediate medical consultation is appropriate, and for general concerns, a pharmacist or doctor may be consulted.


Q: What does the term 'contraindication' mean for Tiostar?

A contraindication is a regulatory term for a condition or factor that absolutely forbids the use of the medicine because it would likely cause harm. For Tiostar, the main contraindication is a known history of serious allergic reactions to the active ingredient.


Q: Why is Tiostar only available by prescription?

Tiostar is the brand name for a formulation of Famotidine, which is regulated to be available in both prescription-strength and lower over-the-counter (OTC) doses. The specific prescription status depends on the strength and the specific indication being treated.


Q: What official body approved Tiostar for use?

The authorization to market and use Tiostar is granted by the relevant government health authority in each country where it is sold. Examples of such bodies include the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

How should Tiostar be stored and disposed of?

How to Store and Dispose of Tiostar (Famotidine)

Storage requirements for Tiostar vary by formulation and must strictly follow regulatory guidance.


Mandatory Storage Conditions

Formulation Required Temperature Stability/Protection Constraints
Oral Tablet/Suspension Controlled Room Temperature (15 to 30 C) Protect from light and moisture; Do not freeze
IV Solution Concentrate Refrigeration (2 to 8 C) Do not freeze

All forms must be kept out of the sight and reach of children. The oral suspension must be discarded after 30 days of reconstitution and should be shaken before each use. Tablets require storage in well-closed, light-resistant containers.


Disposal Instructions

Unused or expired medication should be disposed of by following local pharmaceutical-waste guidelines or by mixing it with an undesirable substance before disposal in household trash. It is explicitly instructed not to flush this medicine down a toilet or drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tiostar found in:

A-Z Index: